COMBI-v BRAF/MEK Inhibitor Combination Trial Continues to Impress in Melanoma (March 15, 2017)

For advanced melanoma patients with BRAF mutations, two pathway inhibitors are much better than one, according to a study presented at the European Society for Medical Oncology.  The latest data confirm... Continue Reading

Advances in Immunotherapy Starting to Define Cancer Treatment (March 9, 2017)

T cell lymphocyte with receptors to kill cancer cell in cancer immunotherapy A handful of drugs recently developed and approved by the United States Food and Drug Administration are expanding the emerging... Continue Reading

2016-Year in Review: Top Advances in Management of Melanoma (February 1, 2017)

2016 was a year of continued advances in the management of melanoma as a result of advances in precision medicine and immunotherapy. Trial results matured defining the role of BRAF inhibitors and combination... Continue Reading

Choosing Stronger Sunscreen Would Reduce Women’s Melanoma Risk (November 8, 2016)

Doctors estimate that the number of women affected by the deadliest form of skin cancer could be reduced by almost 20% if all women used a sunscreen with a sun protection factor (SPF) of 15 or higher.1 Cancer... Continue Reading

Yervoy® Improves Overall Survival in Fully Resected Stage III Melanoma Patients (October 24, 2016)

Results were presented during the 2016 European Society for Medical Oncology Congress demonstrating that Yervoy® (ipilimumab) compared to placebo improves survival in stage III melanoma patients who are... Continue Reading

Epacadostat Plus Keytruda® Appears Effective in Melanoma (October 11, 2016)

The treatment combination consisting of epacadostat plus Keytruda® (pembrolizumab) appears effective in the treatment of advanced melanoma. Melanoma is a type of skin cancer that often starts in the form... Continue Reading

Cotellic®/Zelboraf® Combo: New Standard of Care for Melanoma (September 20, 2016)

The treatment combination consisting of Cotellic® (cobimetinib) plus Zelboraf® (vemurafenib) improves overall survival for patients with advanced, BRAF (V600) mutation-positive melanoma. These confirmatory... Continue Reading

3-Year Survival Improved with Taflinar®/Mekinist® Combination in Advanced Melanoma (July 21, 2016)

Patients with advanced melanoma who were treated with the combination consisting of Taflinar (dabrafenib) plus Mekinist (trametinib) had a significantly improved survival rate at 3 years compared to those... Continue Reading

Counsyl Announces Major Oncology Expansion to Advance Genetic Screening for Cancer Risk (May 25, 2016)

Counsyl launches oncology business unit, an expanded test to assess risk for inherited forms of cancer, and tools to improve genetic screening rates across the healthcare system Counsyl, a DNA testing... Continue Reading

Check It Out: May is Skin Cancer Awareness Month (May 3, 2016)

Skin cancer is the most commonly diagnosed cancer in the United States. Although the majority of skin cancers fall under basal cell and squamous cell carcinomas (number of cases estimated to be around... Continue Reading

NLN Update on the Lymphedema Treatment Act (March 16, 2016)

Updated March 2016 2016 may well be the year that Congress votes to approve the Lymphedema Treatment Act, which provides a Medicare benefit category for essential compression garments and supplies needed... Continue Reading

Year in Review: Melanoma (February 24, 2016)

After several years of exciting developments in melanoma therapy, progress continued throughout 2015 with FDA approved PD-1 immunotherapy treatments and the first-ever approved oncolytic virus therapy... Continue Reading

Patients With Early-Stage Melanoma And Lung Cancer Among Those Standing To Benefit From Immunotherapy (January 29, 2016)

Excerpted from: Advances in Cancer Research And Treatment: 2015 Year In Review Immunotherapy, a type of biological therapy, is among the most promising areas of cancer treatment advances. This approach... Continue Reading

Opdivo Receives Expanded Approval as Single Agent for Initial Therapy in Melanoma (December 2, 2015)

The United States Food and Drug Administration (FDA) has approved the PD1 inhibitor, Opdivo (nivolumab), as a single agent for initial therapy of advanced melanoma. This is the sixth indication for which... Continue Reading

Yervoy Gets Expanded Approval for Earlier-Stage Melanoma (November 9, 2015)

The United States Food and Drug Administration (FDA) has expanded the approval indication for Yervoy (ipilimumab) to include treatment of stage III melanoma. Melanoma is the most deadly form of skin cancer,... Continue Reading

Imlygic® Approved for Melanoma (October 28, 2015)

Imlygic® (talimogene laherparepvec), the first ever FDA-approved oncolytic virus therapy, has been approved for the treatment of melanoma. The approval is for the treatment of melanoma sites in the skin... Continue Reading

MRA Hails FDA Approval of First Combination Immunotherapy for Melanoma (October 1, 2015)

The Melanoma Research Alliance (MRA) welcomes the U.S. Food and Drug Administration (FDA) decision to approve the use of Bristol-Myers Squibb’s (BMS) nivolumab (Opdivo®) and ipilimumab (Yervoy®) in... Continue Reading

Melanoma Support Community: Information, Support, Hope (September 30, 2015)

  Post questions, comment on discussions and find support about living with melanoma by signing up for CancerConnect’s Melanoma Community. Registering with CancerConnect is fast, free and confidential.... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS